# Keith T. Flaherty

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/keith-t-flaherty/

## Facts

| Field | Value |
| --- | --- |
| Citations | 124,182 |
| Field | Melanoma and MAPK Pathways |
| h-index | 148 |
| i10-index | 510 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5023174631 |
| ORCID iD | https://orcid.org/0000-0002-3402-0478 |
| Works | 1,744 |

## Researcher papers

Showing 12 of 18.

- [Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq](https://scholariq.org/papers/dissecting-the-multicellular-ecosystem-of-metastatic-melanoma-by-single-cell-rna/)
- [Final Version of 2009 AJCC Melanoma Staging and Classification](https://scholariq.org/papers/final-version-of-2009-ajcc-melanoma-staging-and-classification/)
- [Genomic Classification of Cutaneous Melanoma](https://scholariq.org/papers/genomic-classification-of-cutaneous-melanoma/)
- [Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma](https://scholariq.org/papers/defining-t-cell-states-associated-with-response-to-checkpoint-immunotherapy-in/)
- [Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine](https://scholariq.org/papers/potential-role-of-intratumor-bacteria-in-mediating-tumor-resistance-to-the/)
- [A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade](https://scholariq.org/papers/a-cancer-cell-program-promotes-t-cell-exclusion-and-resistance-to-checkpoint/)
- [Mechanisms of resistance to immune checkpoint inhibitors](https://scholariq.org/papers/mechanisms-of-resistance-to-immune-checkpoint-inhibitors/)
- [Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma](https://scholariq.org/papers/integrative-molecular-and-clinical-modeling-of-clinical-outcomes-to-pd1-blockade/)
- [EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib](https://scholariq.org/papers/egfr-mediated-reactivation-of-mapk-signaling-contributes-to-insensitivity-of-i/)
- [<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors](https://scholariq.org/papers/i-ras-i-mutations-in-cutaneous-squamous-cell-carcinomas-in-patients-treated-with/)
- [SARS-CoV-2 viral load is associated with increased disease severity and mortality](https://scholariq.org/papers/sars-cov-2-viral-load-is-associated-with-increased-disease-severity-and/)
- [Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors](https://scholariq.org/papers/efficacy-and-safety-of-abemaciclib-an-inhibitor-of-cdk4-and-cdk6-for-patients/)

## Researcher topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.